Evidence map›Paper›PMID 28858910›Full record

ReviewCurrent opinion in nephrology and hypertension2017

Digital pathology in nephrology clinical trials, research, and pathology practice.

Laura Barisoni, Jeffrey B Hodgin

Abstract readReview
In one paragraph

Review in Current opinion in nephrology and hypertension, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Quantification of Glomerular Structural Lesions: Associations With Clinical Outcomes and Transcriptomic Profiles in Nephrotic Syndrome.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2022
    Observational
  10. Article
  11. Cellular and molecular interrogation of kidney biopsy specimens.Current opinion in nephrology and hypertension · 2022
    Review
  12. [Application Test of the AI-Automatic Diagnostic System for Ki-67 in Breast Cancer].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2021
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Artificial intelligence in nephropathology.Nature reviews. Nephrology · 2020
    Article
  18. Extracellular Matrix in Kidney Fibrosis: More Than Just a Scaffold.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2019
    Review
  19. The use of digital pathology and image analysis in clinical trials.The journal of pathology. Clinical research · 2019
    Article
  20. CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2019
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Laura BarisoniaDepartment of Pathology, University of Miami, Miller School of Medicine, Miami, Florida, USA bDepartment of Pathology, University of Michigan, Ann Arbor, Michigan, USA.
Jeffrey B Hodgin

Funding

Training Program in Clinical & Translationa Research in Human Glomerular DiseaseU54DK083912 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GIPSON, DEBBIE S · 2009 to 2023
$20.3M
NIDDK NIH HHS U54 DK083912
6 · The paper itself

Abstract

purpose of reviewIn this review, we will discuss (i) how the recent advancements in digital technology and computational engineering are currently applied to nephropathology in the setting of clinical research, trials, and practice; (ii) the benefits of the new digital environment; (iii) how recognizing its challenges provides opportunities for transformation; and (iv) nephropathology in the upcoming era of kidney precision and predictive medicine. RECENT

findingsRecent studies highlighted how new standardized protocols facilitate the harmonization of digital pathology database infrastructure and morphologic, morphometric, and computer-aided quantitative analyses. Digital pathology enables robust protocols for clinical trials and research, with the potential to identify previously underused or unrecognized clinically useful parameters. The integration of digital pathology with molecular signatures is leading the way to establishing clinically relevant morpho-omic taxonomies of renal diseases. SUMMARY: The introduction of digital pathology in clinical research and trials, and the progressive implementation of the modern software ecosystem, opens opportunities for the development of new predictive diagnostic paradigms and computer-aided algorithms, transforming the practice of renal disease into a modern computational science.

Indexed as

AlgorithmsBiomedical ResearchBiotechnologyClinical Trials as TopicComputersHumansImage Processing, Computer-AssistedKidneyKidney DiseasesMicroscopyNephrologyPathologyPrecision MedicineSoftwareTelemedicine

Identifiers

PMID28858910
PMCPMC5955389

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.